-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UDm2jXX+2l/Hnit7alBypxH1GQZ3OnwzjFpu8dFcwW5oJogigPD45J/5tNqvq6gO a+yEc+zG/JfAP2nkx36Jqg== 0001004878-09-000243.txt : 20100105 0001004878-09-000243.hdr.sgml : 20100105 20091102175404 ACCESSION NUMBER: 0001004878-09-000243 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20091102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 CORRESP 1 filename1.txt HART & TRINEN, LLP ATTORNEYS AT LAW 1624 Washington Street Denver, CO 80203 William T. Hart, P.C. ________ Email: harttrinen@aol.com Donald T. Trinen Facsimile: (303) 839-5414 (303) 839-0061 November 2, 2009 Rose Zukin Mailstop 4720 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Cel-Sci Corporation Registration Statement on Form S-3 File No. 333-161504 This letter provides the Company's responses to the comment received from the staff by letter dated November 2, 2009. The "anti-dilution" provisions of the Series K warrants provide that if the warrant exercise price decreases, the number of shares issuable upon the exercise of the warrants increases. Consequently, if the warrant exercise price was reset to $0.20, and if all remaining Series K warrants were exercised, the proceeds to CEL-SCI from the exercise of warrants would be the same, although CEL-SCI would be required to issue more shares. The second bullet point of the Risk Factor which is the subject of the staff's comment states that if the warrant exercise price decreases the number of shares issuable upon the exercise of the warrants will increase. Very Truly Yours, HART & TRINEN, L.L.P. By: /s/ William T. Hart William T. Hart WTH:ap -----END PRIVACY-ENHANCED MESSAGE-----